article thumbnail

Pfizer planning steep price hike for COVID-19 vaccine

Bio Pharma Dive

The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.

Vaccine 348
article thumbnail

How did pharma develop a vaccine so quickly?

World of DTC Marketing

OBSERVATION: Biologics can take a long time to develop but COVID vaccines have been in development for almost 50 years and novel approaches were used to develop these vaccines. Vaccines typically take 10 to 15 years to develop, test and release to the public. The coronavirus vaccines, however, took less than a year.

Vaccine 307
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

EC approves Bavarian Nordic’s chikungunya vaccine marketing

Pharmaceutical Technology

The EC has authorised the marketing of Bavarian Nordic's Vimkunya chikungunya vaccine for individuals as young as 12 years old.

Vaccine 162
article thumbnail

SK Bioscience gains UK authorisation for SKYCovion Covid-19 vaccine

Pharmaceutical Technology

SK Bioscience has received marketing authorisation from the UK’s medicines and healthcare products regulatory agency (MHRA) for its Covid-19 vaccine, SKYCovion. The authorisation allows the distribution of the vaccine in Scotland, Wales and England.

Vaccine 298
article thumbnail

Optimism on Pfizer COVID vaccine is unwarranted

World of DTC Marketing

You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. The answer lies in looking at Pfizer’s stock price which shot up on the news as well as the false optimism of the stock market. The media has not been helpful.

Vaccine 286
article thumbnail

Valneva and LimmaTech partner for shigellosis vaccine development

Pharmaceutical Technology

Valneva and LimmaTech have signed a deal to potentially develop the first marketed shigellosis vaccine.

Vaccine 246
article thumbnail

BioNTech targets infectious diseases for vaccine development

Pharmaceutical Technology

Following on from its Covid-19 vaccine programmes, BioNTech has set its sights on a range of infectious diseases for vaccine development. The company saw major successes with its Covid-19 vaccine, developed in collaboration with Pfizer. In response to the lower vaccine sales forecasts, BioNTech shares opened at 3.9%

Vaccine 276